Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 20 3 2021 06 06 287 293 Saba Arshi Department of Allergy and Clinical Immunology, Hazrat Rasoul-E-Akram Hospital, Iran University of Medical Science, Tehran, Iran Sepideh Darougar Department of Pediatrics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran Mohammad Nabavi Department of Allergy and Clinical Immunology, Hazrat Rasoul-E-Akram Hospital, Iran University of Medical Science, Tehran, Iran Mohammad Hassan Bemanian Department of Allergy and Clinical Immunology, Hazrat Rasoul-E-Akram Hospital, Iran University of Medical Science, Tehran, Iran Morteza Fallahpour Department of Allergy and Clinical Immunology, Hazrat Rasoul-E-Akram Hospital, Iran University of Medical Science, Tehran, Iran Sima Shokri Department of Allergy and Clinical Immunology, Hazrat Rasoul-E-Akram Hospital, Iran University of Medical Science, Tehran, Iran Javad Ahmadian Department of Pediatric, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran Rasool Molatefi Department of Pediatrics, Bu Ali Hospital, Ardebil University of Medical Sciences, Ardebil, Iran Mahsa Rekabi Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran Zeinab Moinfar Department of Community Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Paniz Hashemitari School of Medicine, Humanitas University, Milan, Italy Narges Eslami Department of Allergy and Clinical Immunology, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2020 08 06 2021 02 07 Asthmatic patients may have aspirin-exacerbated respiratory disease and experience acute dyspnea and nasal symptoms within 3 hours after the ingestion of aspirin. This study aimed to evaluate the effect and outcome of daily low-dose aspirin in the treatment of moderate to severe asthma in patients with concomitant aspirin hypersensitivity and chronic rhinosinusitis with nasal polyposis (CRSwNP). This clinical trial was conducted from February 2014 to February 2015 on 46 adult patients with moderate to severe asthma accompanied by CRSwNP. Patients with a positive aspirin challenge were blindly randomized in three groups receiving placebo/day (A); aspirin 100 mg/day (B); and aspirin 325mg/day (C), respectively. Clinical findings, FEV1 and ACT scores were recorded and compared before, during, and after treatment for 6 months. Of 46 participants at baseline, 30 patients completed this 6-month trial study. The level of asthma control was significant; based on Asthma Control Test (ACT) when comparing the results in groups A and C and also groups B and C, but it was not significant when comparing ACT scores between groups A and B. FEV1 before and after treatment was significant when comparing groups A and B, groups A and C, and groups B and C. To conclude, aspirin desensitization with a daily dose of 325 mg aspirin resulted in the improvement of long-term control of asthma. A daily aspirin dose of 100 mg was not associated with such an increase in ACT score. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2925 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/2925/1702